AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06785753
Drug: Irrigation Solution
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline will be used as irrigation solution
Trial: NCT06194799
Drug: ACP-204
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACP-204 30 mg given once daily, as capsule OR ACP-204 60 mg given once daily, as capsule
Trial: NCT06566079
Drug: ISM6331
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment.
Trial: NCT05423717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken orally, once daily in the evening during the treatment period.
Trial: NCT05754983
Drug: Solid tumor patients receiving immunotherapy for the first time were included in the study
RxNorm normalized name: The New Parent First Aid KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solid tumor patients receiving immunotherapy were included in the study. Baseline information before treatment (including demographic characteristics, basic diseases and their medication history, tumor and anti-tumor history, quality of life scores, etc.) and follow-up information after treatment (PFS, OS, etc.) were collected to summarize factors that may affect the efficacy and prognosis of patients receiving immunotherapy
Trial: NCT06339788
Drug: HD-P023
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose administration of HD-P023
Trial: NCT06589986
Drug: RO7790121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7790121 will be administered as IV infusion. RO7790121 will be administered as SC injection.
Trial: NCT06589986
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching IV RO7790121. Placebo matching SC RO7790121.
Trial: NCT06745336
Drug: CS-001
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-001 Topical Treatment
Trial: NCT06745336
Drug: Placebo Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Topical Solution
Trial: NCT06642545
Drug: Albumin-bound Paclitaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg/m2,intravenous infusion, D1-8, every 3 weeks
Trial: NCT06719544
Drug: enlicitide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT06300463
Drug: AGEN1423
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg IV Q3W
Trial: NCT06037980
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2 given orally twice daily on days 1 to 14 of a 3 weekly cycle for a total of 8 cycles
Trial: NCT05843786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during 5 days
Trial: NCT04699747
Drug: F-18 3F4AP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
Trial: NCT05270525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
Trial: NCT04539366
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06752486
Drug: Giving post photorefractive keratectomy for pain relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We plan to conduct a randomized prospective study to assess the efficacy and safety of oral Gabapentin versus oral Diclofenac Potassium for postoperative analgesia in adults undergoing surface ablation. The first group will be given gabapentin orally in a dose of 300mg Tid for 72 hours and the second group will be given oral diclofenac potassium 50mg Tid for 72 hours. The drugs will be administered starting from the first day postoperative.
Trial: NCT06724016
Drug: HM16390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM16390 will be administered subcutaneously using syringes (35mg/mL) on Day 1 of every 3-week treatment cycle
Trial: NCT05507970
Drug: MMV367
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose dispersed in sterile water, fasted.
Trial: NCT05507970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Dose dispersed in sterile water, fasted.
Trial: NCT05507970
Drug: MMV367 (Fed 440mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose dispersed in sterile water with a high fat meal.
Trial: NCT05507970
Drug: MMV367
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
Trial: NCT05507970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose dispersed in sterile water, fasted, administered for 3 consecutive days.
Trial: NCT05514353
Drug: Vehicle Cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Vehicle Cream formulation contains the same excipients as the active cream
Trial: NCT05349006
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose related to weigh (100 mg for weight ≤ 50 kg and 150 mg for weight \> 50 kg) = 2 to 4 50mg oral caps, daily, during all the study period
Trial: NCT04468360
Drug: Allopregnanolone (Allo) with Dexolve in 0.9% saline for injection manufactured by University of California, Davis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expt. 1 (extinction retention): On Day 2, a 1.7 ug/kg IV bolus of Allo will be administered over 5 minutes at the completion of extinction training and continued as a 5-hour drip to maintain resting plasma Allo levels at \~1500 pg/ml. Expt. 2 (reconsolidation blockade): On Day 2, a 28 ug/kg IV bolus of Allo will be infused over 30 minutes immediately following presentation of a single CS+.
Trial: NCT06723080
Drug: VC005 Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VC005 Placebo group repeat administration
Trial: NCT06687941
Drug: AST-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-201 is administered intravenously on Days 1, 8, and 15 of each 28-day cycle, followed by a one-week rest period. Dosing is repeated until DLT or disease progression is occurred.
Trial: NCT05701917
Drug: Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulants are a group of medications that decrease your blood's ability to clot.
Trial: NCT06725017
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05417321
Drug: HB0036
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0036 via intravenous infusion. HB0036 IV every 3 weeks (q3w).
Trial: NCT06192615
Drug: Intravenous Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo of 0.9% saline administered over 40 minutes
Trial: NCT06192615
Drug: Sublingual Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert sublingual film
Trial: NCT05485805
Drug: Naproxen sodium and caffeine (BAY2880376)
RxNorm normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral use, single dose
Trial: NCT05485805
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral use, single dose
Trial: NCT05485805
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, oral use, single dose
Trial: NCT06440005
Drug: AGX101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody Drug Conjugate
Trial: NCT04755595
Drug: Botox Cosmetic Injectable Product
RxNorm normalized name: Botox Cosmetic Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine release inhibitor and a neuromuscular blocking agent
Trial: NCT05849727
Drug: TQH3821 tablets 200 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
Trial: NCT05849727
Drug: TQH3821 tablets matching placebo
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQH3821 tablets matching placebo without active substance.
Trial: NCT06761586
Drug: AUR104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once or twice a day
Trial: NCT06359782
Drug: C1 Esterase Inhibitor Injection [Cinryze]
RxNorm normalized name: C1 esterase inhibitor Injection [Cinryze]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 Esterase Inhibitor Injection \[Cinryze\]
Trial: NCT06359782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
Trial: NCT06400121
Drug: Apimostinel Infusion, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of Apimostinel (10mg)
Trial: NCT06400121
Drug: Isotonic Solution, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection of placebo
Trial: NCT04643002
Drug: SAR439459
RxNorm normalized name: MAB HUMAN (IGG4) ANTI P01137 (TGFB1_HUMAN) OR ANTI P61812 (TFGB2_HUMAN) OR ANTI P10600 (TGFB3_HUMAN)(SAR439459)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Trial: NCT06798025
Drug: Punctal dilation and topical medication
RxNorm normalized name: zinc pyrithione Medicated Shampoo [Free and Clear]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with a combination of punctal dilation and topical medication in the form of preservative-free steroid eye drops based on dexamethasone sodium phosphate (0.1%) and preservative-free artificial tears based on sodium hyaluronate, polyethylene, and propylene Glycol.
Trial: NCT05966064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo randomized at baseline and after 3 months
Trial: NCT05063786
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 or 1000 mg/m2 (per investigator preference) twice a day (BID) oral, 2 weeks on, 1 week off, every 3 weeks.
Trial: NCT06384976
Drug: Standard lymphodepletion regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYC/FLU
Trial: NCT06401538
Drug: BMB-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMB-101 liquid administered orally twice a day for 3 months
Trial: NCT05198960
Drug: Direct Oral Anticoagulants
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to receive DOAC, at the choice of the investigator: Apixaban 2.5 mg both in day or Rivaroxaban 10 mg once daily.
Trial: NCT06537999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Day 1: IV infusion of placebo~* Week 1 to Week 15: placebo administered SC every 2 weeks
Trial: NCT05599048
Drug: Hyperpolarized 13C-Pyruvate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05599048
Drug: 13C,15N-Urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06547151
Drug: AMOR-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational arm: Tablets containing 250mg elemental calcium from Amorphous Calcium Carbonate (ACC).
Trial: NCT06547151
Drug: Crystalline Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm: Crystalline Calcium Carbonate (CCC) oral tablet contains 500 mg elemental calcium.
Trial: NCT06597201
Drug: glucose peritoneal dialysis solution
RxNorm normalized name: glucose Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received conventional treatment with glucose peritoneal dialysis solution (lactate), which must include 1.5% glucose peritoneal dialysate (lactate) (2L) once.
Trial: NCT05338632
Drug: Narcan 40 MG/ML Nasal Spray
RxNorm normalized name: Narcan 40 MG/ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone 4mg/0.1 mL intranasal spray, up to 4 doses intranasally, followed by 1ml 0.4 mg/ml naloxone hydrochloride intravenously
Trial: NCT06758882
Drug: Androgen receptor (AR) inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of androgen deprivation therapy
Trial: NCT05757167
Drug: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
RxNorm normalized name: artemether-lumefantrine 20 mg-120 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets: 6 doses of 80/480 mg over 3 days
Trial: NCT06747520
Drug: ET-26HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose is 0.8 mg/kg, single dose, Infusion time was 60s ± 5s.
Trial: NCT06746701
Drug: Nucleotide Analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starting from the first day of enrollment, take NA orally once a day.
Trial: NCT04656418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buffer without active ingredient
Trial: NCT06770114
Drug: Cetylpyridinium Chloride and Zinc Lactate Mouthwash
RxNorm normalized name: cetylpyridinium chloride / zinc chloride Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 .075 % cetylpyridinium chloride and 0 .28 % zinc lactate
Trial: NCT06770114
Drug: PhosFlur Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 .044 % sodium fluoride
Trial: NCT05681442
Drug: continuous pivotal βL-AB
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous pivotal βL-AB
Trial: NCT05681442
Drug: intermittent pivotal βL-AB
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intermittent pivotal βL-AB (IID = control group)
Trial: NCT05681442
Drug: AG infusion for 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AG infusion for 5 days (ACT Group)
Trial: NCT06762600
Drug: HRS-4729 injection placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS-4729 injection placebo
Trial: NCT06762600
Drug: HRS9531 injection placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9531 injection placebo
Trial: NCT06762600
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen
Trial: NCT06752590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets once daily
Trial: NCT06767085
Drug: Saline spray
RxNorm normalized name: Saline Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline spray on the cervix and cervical canal 5-7 minutes prior to the procedure
Trial: NCT05508737
Drug: Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: arms : Pembrolizumab 400 mg every 6 weeks (Q6W), trifluridine/tipiracil at 35 or 30 mg/m2 twice daily (BID) for 5 days a week (D1-5, D8-12) with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks (Q4W)
Trial: NCT05333471
Drug: MTP 101-LF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each unit of MTP-101-LF contains approximately 35 mL of fecal transplant product. Participants will receive approximately 32 mL via colonoscopy.
Trial: NCT06740188
Drug: 5-hydroxytryptamine balanced antidepressants trazodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention group was given only 5-hydroxytryptamine balanced antidepressants trazodone
Trial: NCT06191315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Trial: NCT06372145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Tablet-Route of administration:oral
Trial: NCT05973851
Drug: Second-line Antidepressants
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See arm description
Trial: NCT05557045
Drug: JZP815
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JZP815 will be administered as oral capsules to participants BID approximately 12 hours apart, in the morning and in the evening. QD dosing may also be investigated, if supported by PK data.
Trial: NCT04584983
Drug: usual prescribed intralipid (UL) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid will be started at 1 g/kg/day and routinely advanced by 1 g/kg/day each day to a max of 3 g/kg/day as per usual clinical practice
Trial: NCT04584983
Drug: restricted prescribed intralipid (RL) regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid will be started at 0.5 g/kg/day and routinely advanced by 0.5 g/kg/day each day to a max of 1.5 g/kg/day (half rate of usual clinical practice).
Trial: NCT06761417
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1000 mg/m\^2, d1-14, bid; Each 21-day cycle was used for a total of 4-6 cycles.
Trial: NCT06754085
Drug: Florastamin[18F] Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be intravenously injected with a single dose of 7±1 mCi (259±37 MBq) of Florastamin\[18F\] Injection and undergo PET/CT scan at 60-110 min after the injection.
Trial: NCT06767527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via IV infusion
Trial: NCT06758544
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 days/cycle, administered up to 6 cycles
Trial: NCT06767683
Drug: ALKS 2680, 4mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet containing 4 mg of ALKS 2680 for once daily administration
Trial: NCT06767683
Drug: ALKS 2680, 6mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet containing 6 mg of ALKS 2680 for once daily administration
Trial: NCT06767683
Drug: ALKS 2680, 8mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet containing 8 mg of ALKS 2680 for once daily administration
Trial: NCT06778850
Drug: MDR-001
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of small molecule MDR-001 tablets
Trial: NCT06778850
Drug: palcebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally placebo
Trial: NCT06791161
Drug: Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRCA1/2 mutated hormone receptor-positive HER2-negative early high-risk breast cancer is treated with 3 3 treatment options after surgery：Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor
Trial: NCT06388083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT06609928
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06775275
Drug: Adebellizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adebrelimab
Trial: NCT06774846
Drug: Acetylsalicylic acid/Aspirin (100 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 100 mg acetylsalicylic acid (or Aspirin) orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
Trial: NCT06774846
Drug: Placebo acetylsalicylic acid (100 mg) / 0.9% sodium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients in the placebo group will receive 100 mg placebo acetylsalicylic acid orally (tablet) once a day (or intravenously if oral administration is not possible in the acute phase of pneumonia), introduced within 84 hours of pneumonia diagnosis, for 90 days.
Trial: NCT06765954
Drug: M-CENK (Activated NK Cells)
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously (IV) before and after radiation therapy, also with variations in the timing and dosing across different cohorts.
Trial: NCT06759181
Drug: anti-BCMA/FcRL5 CAR T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-BCMA/FcRL5 autologous CAR T cells will be infused at a dose ranging from 1 - 2 x 10\^6/kg CAR+ T cells after receiving lymphodepleting chemotherapy.~Other Name:
Trial: NCT06747923
Drug: SB17170
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking SB17170 orally once a day
Trial: NCT06747923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taking Placebo orally once a day
Trial: NCT06748014
Drug: MPFF
RxNorm normalized name: Micronized Purified Flavonoid Fraction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 3000 mg 7 day then 1000 mg 2 months
Trial: NCT06750991
Drug: CDR-CHOP
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rituximab 375 mg/m2 D1 Cyclophosphamide 750 mg/m2 D2 Doxorubicin 50 mg/m2 D2 Vincristine 1.4 mg/m2 D2 Prednisone 69 mg.m2 D2-6 Chidamide 20 mg/d D1,4,8,11 Decitabine 10 mg/m2 D-5 - -1
Trial: NCT06750744
Drug: Tigecycline (Tygacil)
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: selective antibiogram
Trial: NCT05418101
Drug: VIS171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive VIS171 via SC route of administration.
Trial: NCT05418101
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Placebo via SC route of administration